Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
Julia Foldi(Yale University), Lajos Pusztai(Yale Cancer Center)
Cited by 67
Related Papers
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
|Annals of Oncology|2018|774
Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma
|Cancer|2003|176
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
|Journal for ImmunoTherapy of Cancer|2020|126